SNT rejection syndrome (SRS) is a life-threatening immunological response in which the body's immune system attacks the Synthetic Neurovascular Tissue bonding layer, resulting in rapid necrosis of both the SNT and surrounding organic tissue.

INCIDENCE: 0.6% of standard implantation procedures. Higher rates observed in patients with:
— Pre-existing autoimmune conditions (3.2%)
— Multiple simultaneous implants (1.8%)
— Black-market SNT of unknown generation or origin (12-18%)
— Prior SNR (Synthetic Necrotic Reversion) exposure, even partial (8.4%)

CLINICAL PRESENTATION:
Phase 1 (Hours 1-6): Localized erythema and edema at implant site. Patient reports burning sensation. Implant function degrades.
Phase 2 (Hours 6-24): Necrotic tissue visible at bonding margins. SNT begins to liquefy. Patient reports severe pain and loss of implant sensation. Fever exceeds 39°C.
Phase 3 (Hours 24-72): Full bonding failure. Implant becomes mechanically loose. Risk of hemorrhage if vascular integration was established. Sepsis risk from necrotic tissue.
Phase 4 (72+ hours without treatment): Systemic inflammatory response. Multi-organ failure. Death.

EMERGENCY MANAGEMENT:
Immediate surgical explantation of the implant and debridement of all necrotic tissue. Broad-spectrum antimicrobials. Anti-inflammatory cascade inhibitors. Psychological support — involuntary loss of an integrated implant is consistently described by patients as comparable to amputation.

NOTE ON BLACK-MARKET SNT:
Counterfeit and expired SNT is the single largest contributor to rejection events in the GLMZ. Street-grade SNT sold by unlicensed rippers may be Gen 3 or Gen 4 material relabeled as Gen 7, expired surgical stock diverted from hospital waste streams, or synthetic material that was never SNT at all. The Shelf has the highest per-capita rejection rate in the GLMZ, directly correlated with the prevalence of unlicensed augmentation clinics.